Navigation Links
Isis Favorably Revises Financial Guidance and Introduces Mipomersen as Generic Name for ISIS 301012
Date:10/8/2007

- ISIS 301012 given generic name mipomersen sodium - Isis further reduces its 2007 net operating loss guidance to mid to high

$20 million range

- Isis will host a conference call this morning at 8:00 a.m. E.T. at

http://www.isispharm.com

CARLSBAD, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that the United States Adopted Names Council has approved the nonproprietary name mipomersen sodium for ISIS 301012, a cholesterol-lowering drug targeting apolipoprotein B-100. In addition, Isis is reducing its recently revised pro forma net operating loss (NOL) guidance downward from mid to high $40 million range to mid to high $20 million range, excluding non-cash compensation expense. Isis' initial guidance for its 2007 NOL was in the mid to high $60 million range. These announcements, along with ISIS 301012 Phase 2 results presented at the Drugs Affecting Lipid Metabolism (DALM) XVI International Symposium, will be discussed in a conference call hosted by Isis this morning at 8:00 a.m. E.T.

"We recently announced our acquisition of Symphony GenIsis as well as closure of our collaboration with Ortho-McNeil, Inc. and the immediate achievement of the first milestone in that collaboration. We are revising our net operating loss guidance to reflect the favorable financial impact of these transactions; we now expect that our 2007 NOL will be in the mid to high $20 million range," said B. Lynne Parshall, Executive Vice President and Chief Financial Officer, Isis Pharmaceuticals. "When we revised our cash guidance in our second quarter conference call, we had already taken into account the anticipated cash impact of both the Ortho-McNeil collaboration and the Symphony GenIsis purchase, so we continue to estimate that, based on reasonable assumptions for new sources of revenue and cash, we have sufficient resources to meet our anticipated funding requirements through at least the end of 2010."

Conference Call Information

At 8:00 a.m. Eastern Time Monday, October 8, Isis will conduct a live webcast conference call to discuss ISIS 301012 results. Interested parties may access the webcast at http://www.isispharm.com or listen to the call by dialing 888-211-7384 (U.S.) / 913-312-0380 (International). A replay will be available for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for a wide variety of diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding Isis Pharmaceuticals' business, its financial outlook, its business development accomplishments and the therapeutic potential of Isis' products in development. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2006, and its quarterly report on Form 10-Q for the quarter ended June 30, 2007, which are on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals, Ibis Biosciences and Ibis T5000 are registered trademarks or trademarks of Isis Pharmaceuticals, Inc.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Study Revises Dynamins Role in Nerve Cell Function
2. Financial Allowances Being Offered To Poor Vietnamese HIV Carriers
3. NHS Audit Commission Warns Possible Financial Collapse In Sussex And Surrey
4. Health conditions and patient treatment affected by a financial crunch
5. NHS financial crisis may lead to roll back of flexi-work scheme and private acquisition
6. Bird Flu: Fear of the Unknown Could Put Financial Markets in a Soup
7. Huge financial losses due to Bird flu scare!
8. Sexual Health Service Is Under Pressure and Faced With Financial Challenges
9. Elective Surgery - the Financial Whipping Boy
10. British Hospitals Face Financial Crisis
11. Kidney donors do not realize financial gains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... Houston dentist , Dr. Behzad ... Dental Center. Currently, patients can get single dental implants for $3,599 and All ... learn more about these offers by contacting Antoine Dental Center. Both of these ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald ... officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio University ...
(Date:2/24/2017)... Texas (PRWEB) , ... February 24, 2017 , ... ... to The Medical Center at Craig Ranch building at 8080 State Highway 121, Suite ... Medical District with easy access to Highway 121. , As the practice has grown, ...
(Date:2/24/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has published a ... an astounding statement when he says that the entire Bible was written for the ... times so plainly that anyone should be able to see the time period. He ...
(Date:2/24/2017)... Lawn, NJ (PRWEB) , ... February 24, 2017 ... ... with robust marketing services, which specializes in thought leadership , media relations, ... marketing campaigns and services that will be powered through Act-On, an intuitive marketing ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 24, 2017 Medical information groups within ... their self-service capabilities to manage inquiries from external ... New research from consulting leader Best Practices, ... self-service website portals where HCPs can sign on ... of many findings to emerge from the new ...
(Date:2/24/2017)... Februar 2017 ITL Limited, ( ASX: ... ist erfreut, für das zum 31. Dezember 2016 ... exzellente Ergebnisse vorlegen zu können. Eine vollständige Präsentation ... finden Sie hier . ... 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 ... gives comprehensive insights on the various drugs ... The report covers all the drugs that ... Preclinical & Clinical). The pipeline focuses on ... small molecules, antibodies, stem cell therapies, recombinant ...
Breaking Medicine Technology: